1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016

  • May 2016
  • -
  • Global Markets Direct
  • -
  • 734 pages

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Diffuse Large B-Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma
- The report reviews pipeline therapeutics for Diffuse Large B-Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diffuse Large B-Cell Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Diffuse Large B-Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diffuse Large B-Cell Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
Introduction 6
Diffuse Large B-Cell Lymphoma Overview 7
Therapeutics Development 8
Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 10
Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 15
Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 16
Diffuse Large B-Cell Lymphoma - Products under Development by Companies 19
Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 27
Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 28
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 99
Drug Profiles 114
Diffuse Large B-Cell Lymphoma - Recent Pipeline Updates 413
Diffuse Large B-Cell Lymphoma - Dormant Projects 708
Diffuse Large B-Cell Lymphoma - Dormant Projects 708
Diffuse Large B-Cell Lymphoma - Discontinued Products 711
Diffuse Large B-Cell Lymphoma - Product Development Milestones 713
Appendix 719

List of Tables
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2016 22
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2016 23
Number of Products under Development by Companies, H1 2016 24
Number of Products under Development by Companies, H1 2016 (Contd..1) 25
Number of Products under Development by Companies, H1 2016 (Contd..2) 26
Number of Products under Development by Companies, H1 2016 (Contd..3) 27
Number of Products under Development by Companies, H1 2016 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Comparative Analysis by Late Stage Development, H1 2016 30
Comparative Analysis by Clinical Stage Development, H1 2016 31
Comparative Analysis by Early Stage Development, H1 2016 32
Products under Development by Companies, H1 2016 33
Products under Development by Companies, H1 2016 (Contd..1) 34
Products under Development by Companies, H1 2016 (Contd..2) 35
Products under Development by Companies, H1 2016 (Contd..3) 36
Products under Development by Companies, H1 2016 (Contd..4) 37
Products under Development by Companies, H1 2016 (Contd..5) 38
Products under Development by Companies, H1 2016 (Contd..6) 39
Products under Development by Companies, H1 2016 (Contd..7) 40
Products under Investigation by Universities/Institutes, H1 2016 41
Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc., H1 2016 42
Diffuse Large B-Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 43
Diffuse Large B-Cell Lymphoma - Pipeline by Affimed GmbH , H1 2016 44
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H1 2016 45
Diffuse Large B-Cell Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 46
Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 47
Diffuse Large B-Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016 48
Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca Plc, H1 2016 49
Diffuse Large B-Cell Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 50
Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H1 2016 51
Diffuse Large B-Cell Lymphoma - Pipeline by BeiGene, Ltd., H1 2016 52
Diffuse Large B-Cell Lymphoma - Pipeline by BIND Therapeutics, Inc., H1 2016 53
Diffuse Large B-Cell Lymphoma - Pipeline by Biocon Limited, H1 2016 54
Diffuse Large B-Cell Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 55
Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 56
Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H1 2016 57
Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, L.L.C., H1 2016 58
Diffuse Large B-Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 59
Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 60
Diffuse Large B-Cell Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016 61
Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H1 2016 62
Diffuse Large B-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 63
Diffuse Large B-Cell Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H1 2016 64
Diffuse Large B-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016 65
Diffuse Large B-Cell Lymphoma - Pipeline by EpiZyme, Inc., H1 2016 66
Diffuse Large B-Cell Lymphoma - Pipeline by Erytech Pharma SA, H1 2016 67
Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 68
Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H1 2016 69
Diffuse Large B-Cell Lymphoma - Pipeline by Genosco, H1 2016 70
Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 71
Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016 72
Diffuse Large B-Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016 73
Diffuse Large B-Cell Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 74
Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016 75
Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H1 2016 76
Diffuse Large B-Cell Lymphoma - Pipeline by Immunovaccine, Inc., H1 2016 77
Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H1 2016 78
Diffuse Large B-Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H1 2016 79
Diffuse Large B-Cell Lymphoma - Pipeline by Johnson and Johnson, H1 2016 80
Diffuse Large B-Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 81
Diffuse Large B-Cell Lymphoma - Pipeline by Karus Therapeutics Limited, H1 2016 82
Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 83
Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016 84
Diffuse Large B-Cell Lymphoma - Pipeline by Mabion SA, H1 2016 85
Diffuse Large B-Cell Lymphoma - Pipeline by mAbxience S.A., H1 2016 86
Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2016 87
Diffuse Large B-Cell Lymphoma - Pipeline by Medivation, Inc., H1 2016 88
Diffuse Large B-Cell Lymphoma - Pipeline by Merck and Co., Inc., H1 2016 89
Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 90
Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016 91
Diffuse Large B-Cell Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016 92
Diffuse Large B-Cell Lymphoma - Pipeline by Molplex Ltd., H1 2016 93
Diffuse Large B-Cell Lymphoma - Pipeline by MorphoSys AG, H1 2016 94
Diffuse Large B-Cell Lymphoma - Pipeline by Neumedicines Inc., H1 2016 95
Diffuse Large B-Cell Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H1 2016 96
Diffuse Large B-Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016 97
Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H1 2016 98
Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 99
Diffuse Large B-Cell Lymphoma - Pipeline by Pfizer Inc., H1 2016 100
Diffuse Large B-Cell Lymphoma - Pipeline by Philogen S.p.A., H1 2016 101
Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 102
Diffuse Large B-Cell Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016 103
Diffuse Large B-Cell Lymphoma - Pipeline by RedHill Biopharma Ltd., H1 2016 104
Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H1 2016 105
Diffuse Large B-Cell Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 106
Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz International GmbH, H1 2016 107
Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 108
Diffuse Large B-Cell Lymphoma - Pipeline by Selvita S.A., H1 2016 109
Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 110
Diffuse Large B-Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 111
Diffuse Large B-Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016 112
Assessment by Monotherapy Products, H1 2016 113
Assessment by Combination Products, H1 2016 114
Number of Products by Stage and Target, H1 2016 116
Number of Products by Stage and Mechanism of Action, H1 2016 121
Number of Products by Stage and Route of Administration, H1 2016 125
Number of Products by Stage and Molecule Type, H1 2016 127
Diffuse Large B-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 427
Diffuse Large B-Cell Lymphoma - Dormant Projects, H1 2016 722
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..1), H1 2016 723
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..2), H1 2016 724
Diffuse Large B-Cell Lymphoma - Discontinued Products, H1 2016 725
Diffuse Large B-Cell Lymphoma - Discontinued Products (Contd..1), H1 2016 726

List of Figures
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2016 22
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2016 23
Number of Products under Development by Companies, H1 2016 24
Number of Products under Investigation by Universities/Institutes, H1 2016 29
Comparative Analysis by Clinical Stage Development, H1 2016 31
Comparative Analysis by Early Stage Products, H1 2016 32
Assessment by Monotherapy Products, H1 2016 113
Number of Products by Top 10 Targets, H1 2016 115
Number of Products by Stage and Top 10 Targets, H1 2016 115
Number of Products by Top 10 Mechanism of Actions, H1 2016 120
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 120
Number of Products by Routes of Administration, H1 2016 124
Number of Products by Stage and Routes of Administration, H1 2016 124
Number of Products by Top 10 Molecule Types, H1 2016 126
Number of Products by Stage and Top 10 Molecule Types, H1 2016 126

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeli

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeli

  • $ 3 500
  • Industry report
  • July 2016
  • by Global Markets Direct

Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR ...

Histone Deacetylase 1 (EC 3.5.1.98) - Pipeline Review, H1 2016

Histone Deacetylase 1 (EC 3.5.1.98) - Pipeline Review, H1 2016

  • $ 3 500
  • Industry report
  • June 2016
  • by Global Markets Direct

Histone Deacetylase 1 (EC 3.5.1.98) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Histone Deacetylase 1 (EC 3.5.1.98) - Pipeline Review, H1 2016’, provides in depth analysis on Histone ...

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha Polypeptide or Serine/Threonine Protein Kinase PIK3

  • $ 3 500
  • Industry report
  • July 2016
  • by Global Markets Direct

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Alpha Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Alpha or Phosphoinositide 3 Kinase Catalytic Alpha ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.